The ImmuneRACE Study: A Prospective Multicohort Study of Immune Response Action to COVID-19 Events with the ImmuneCODE™ Open Access Database

Dines, J. N.; Manley, T. J.; Svejnoha, E.; Simmons, H. M.; Taniguchi, R.; Klinger, M.; Baldo, L.; Robins, H.

Background: Adaptive Biotechnologies has built an immune medicine platform based on the sequencing of immune receptors (immunoglobulins, B-cell receptors [BCRs] and T-cell receptors [TCRs]) with myriad applications in health and disease. This broad platform technology can be used to assess the diversity of the cellular adaptive immune system and track disease-associated TCRs and BCRs during the course of infection. The SARS-CoV-2 virus is spreading rapidly throughout the world, causing significant morbidity and mortality. Researchers, governments, and biotechnology companies are mobilizing to develop and distribute diagnostic and therapeutic alternatives to try to curb this global pandemic. Methods: In collaboration with our partners LabCorp/Covance, Adaptive Biotechnologies has opened the ImmuneRACE study to prospectively collect samples from individuals who have been infected with SARS-CoV-2, who have recovered from SARS-CoV-2 infection, or who have been exposed to someone infected with SARS-CoV-2. Discussion: We believe that the information contained within the genetics of the adaptive immune response to SARS-CoV-2 can improve our understanding of the immunobiology of this devasting virus and may inform efforts to improve current diagnostic and therapeutic approaches. To facilitate scientific and clinical advancement in the fight against COVID-19, the TCR sequence data resulting from the primary aims of this study will be made publicly available to scientists and researchers across the globe, an effort made possible through a collaboration with Microsoft. Trial registration: ImmunoRACE is registered with the US National Institutes of Health and can be accessed at ClinicalTrials.gov (NCT04494893).